,8,29, 30, 31 In the MA.17 trial, GIM-4 trial, and DATA trial, for example, the benefit of extended aromatase inhibition seemed to be largely limited to patients with ER+/PR+ tumours.7 This evidence concerns the gene ESR1 and neoplasm.